Related Experiment Video
Updated: May 26, 2026

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Diuretics for respiratory distress syndrome in preterm infants
Audra Stewart1, Luc P Brion, Roger Soll
1Neonatal-Perinatal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas, USA, 75390-9063.
Insights
Diuretics like furosemide do not benefit preterm infants with respiratory distress syndrome (RDS) long-term and increase risks. Theophylline also shows no long-term benefits for RDS in preterm infants.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Lung edema is a common complication of respiratory distress syndrome (RDS) in preterm infants.
- Diuretic administration is sometimes used to manage fluid overload in these infants.
Purpose of the Study:
- To evaluate the risks and benefits of using diuretics in preterm infants diagnosed with RDS.
- To synthesize evidence from randomized controlled trials on diuretic use in neonatal RDS.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified through extensive database searches (CENTRAL, MEDLINE, EMBASE) and conference abstracts.
- Inclusion criteria focused on preterm infants (<5 days old) with RDS, randomly assigned to diuretic treatment, with key outcome measures like mortality, patent ductus arteriosus, and renal function.
- Data extraction and analysis followed Cochrane Collaboration standards, with independent review by two investigators.
Main Results:
- Seven studies met the criteria; six evaluated furosemide, predating modern RDS management. Furosemide offered no sustained benefits and increased risks of patent ductus arteriosus and hemodynamic instability.
- A recent study on theophylline showed no long-term advantages, although it transiently improved renal function and reduced oligoanuria without affecting renal function at discharge.
Conclusions:
- Current evidence does not support the routine use of furosemide in preterm infants with RDS.
- The potential risks of furosemide, including hypovolemia and symptomatic patent ductus arteriosus, necessitate careful consideration.
- Insufficient data exist to recommend routine low-dose theophylline administration for preterm infants with RDS.
Background:
Lung edema may complicate respiratory distress syndrome (RDS) in preterm infants.
Objectives:
The aim of this review was to assess the risks and benefits of diuretic administration in preterm infants with RDS.
Search Methods:
The standard search method of the Cochrane Neonatal Review Group was used. The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE and EMBASE were searched. These searches were updated in April 2003, March 2007, January 2011. In addition, the abstract books of the American Thoracic Society and Society for Pediatric Research were searched. MEDLINE and CENTRAL search was conducted using the keyword "Respiratory Distress Syndrome" alone, to find studies of medications recently classified as diuretics, such as theophylline. In addition, EMBASE, controlled-trials.com and clinicaltrials.gov searches were completed in January 2011. MEDLINE search updated to August 2011.
Selection Criteria:
Trials were included in which preterm infants with RDS and less than five days of age were randomly allocated to diuretic administration. Of those trials, studies were only included in which at least one of the following outcomes measures was evaluated: mortality, patent ductus arteriosus, hypovolemic shock, intraventricular hemorrhage, renal failure, duration of oxygen supplementation, duration of mechanical ventilation, need for oxygen supplementation at 28 days of life, oxygen supplementation at 36 weeks of postmenstrual age (gestational age + postnatal age), length of stay, number of rehospitalizations during the first year of life, and neurodevelopmental outcome.
Data Collection And Analysis:
The standard method for the Cochrane Collaboration, which is described in the Cochrane Collaboration Handbook, was used. Two investigators extracted, assessed and coded separately all data for each study. Any disagreement was resolved by discussion.
Main Results:
Seven studies met inclusion criteria. Six studies using furosemide were done before the current era of prenatal steroids, surfactant and fluid restriction. Furosemide administration had no long-term benefits. Furosemide-induced transient improvement in pulmonary function did not outweigh an increased risk for patent ductus arteriosus and for hemodynamic instability. In one recent study, theophylline had no long-term benefits. Theophylline significantly decreased the risk of oligoanuria and transiently increased renal function, but did not significantly affect renal function at discharge or other outcomes.
Authors' Conclusions:
There are no data to support routine administration of furosemide in preterm infants with RDS. Elective administration of furosemide to any patient with RDS should be carefully weighed against the risk of precipitating hypovolemia or developing a symptomatic patent ductus arteriosus. There are not enough data to support routine administration of low-dose theophylline in preterm infants with RDS.
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Breathing
Endoscopic Studies II: Thoracocentesis
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
Pulmonary Cycle: Exhalation
Acute Respiratory Failure-III